Novo Nordisk Says New Obesity Drug Helps Patients Lose Weight in Mid-Stage Trial

Novo Nordisk said a new weight-loss drug candidate led to weight loss and diabetes reductions in both injection and pill versions during a mid-stage trial.

The Danish pharmaceutical company said Tuesday that patients on the drug, amycretin, showed weight loss of up to 14.5% after 36 weeks of treatment. It also achieved significant reductions in blood sugar levels, the company said.